SynCardia’s Total Artificial Heart Rescues LVAD Patient with Right Ventricular Failure
TUCSON, Ariz., Sept. 21, 2011 /PRNewswire/ — SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the SynCardia temporary Total Artificial Heart, announced today that University Hospital of Nantes successfully transplanted 51-year-old Total Artificial Heart patient Louise Mouche after 177 days of support. Mrs. Mouche is a French gypsy who lives with a sedentary group of people approximately 40 km from Nantes.
“We first implanted Mrs. Mouche with a left ventricular assist device (LVAD),” said Prof. Daniel Duveau, Medical Director of the Thorax Institute at University Hospital of Nantes. “However, a few days later, we removed the LVAD because of right ventricular failure and implanted SynCardia’s Total Artificial Heart.”
Mrs. Mouche was implanted with SynCardia’s Total Artificial Heart on Jan. 30, 2011. While supported by the Total Artificial Heart, she was able to exercise several times a day, riding the exercise bike regularly for 30 to 45 minutes at a time.
On April 24, 2011, Mrs. Mouche was switched to the FreedomÃ‚® portable driver, a wearable power supply for SynCardia’s Total Artificial Heart. Three months later, on July 26, 2011, Mrs. Mouche received her matching donor heart. Post-transplant, she was extubated quickly and transferred out of the ICU 8 days later. One month after her transplant, Mrs. Mouche was discharged home with her new donor heart. Today, she is doing very well and participating in a cardiac rehabilitation program.
“SynCardia’s Total Artificial Heart is a very good device with which we have had a lot of successful experiences,” said Prof. Duveau. “It is easy to implant, easy to use and very powerful. The Total Artificial Heart is, in our practice, the best and most efficient device in cases of biventricular failure as reported in a non-randomized study in which we compared the Total Artificial Heart and external biventricular support.”
University Hospital of Nantes has been implanting the Total Artificial Heart since 1988. The hospital has achieved a 75% bridge to transplant rate with the Total Artificial Heart. Five-year and 10-year survival rates after transplantation among this group of patients are 81% and 76% respectively.
SynCardia recognizes and thanks IST Cardiology, the French distributor for the Total Artificial Heart, for their commitment and on-going support of University Hospital of Nantes.
CAUTION – The FreedomÃ‚® portable driver is an investigational device, limited by United States law to investigational use.
About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world’s first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the Total is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. More than 950 implants account for more than 230 patient years of life.
Similar to a heart transplant, SynCardia’s Total Artificial Heart replaces both failing heart ventricles and the four heart valves. It is the only device that eliminates the symptoms and source of end-stage biventricular failure. The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through both ventricles. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.
In March 2011, Fast Company magazine ranked SynCardia #20 among the World’s 50 Most Innovative Companies “for giving mobility to artificial heart recipients.” Also in March, the longest running health and wellness series on public television, “Healthy Body, Healthy Mind,” produced a 30-minute program featuring SynCardia’s Total Artificial Heart. View here
For additional information, please visit: http://www.syncardia.com
Like SynCardia on Facebook
Follow SynCardia on Twitter – @SynCardia
Connect with SynCardia on LinkedIn
SOURCE SynCardia Systems, Inc.